Francesco Greco

Dr. Francesco Greco

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
AMAbir Mukherjee
Abir Mukherjee
DBDivya Bezwada
Divya Bezwada
FGFrancesco Greco
Francesco Greco
MZMalu Zandbergen
Malu Zandbergen
TSTong Shen
Tong Shen
ELErnst Lengyel
Ernst Lengyel

18 April 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
FGFrancesco Greco
Francesco Greco
LQLaura Quercioli
Laura Quercioli
APAngela Pucci
Angela Pucci
SRSilvia Rocchiccioli
Silvia Rocchiccioli
MFMauro Ferrari
Mauro Ferrari
LMLiam Andrew McDonnell
Liam Andrew McDonnell
Atherosclerosis is characterized by fatty plaques in large and medium sized arteries. Their rupture can causes thrombi, occlusions of downstream vessels and adverse clinical events. The investigation of atherosclerotic plaques is made difficult by their highly heterogeneous nature. Here we propose a spatially resolved approach based on matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging to investigate lipids in specific regions of atherosclerotic plaques. The method was applied to a small dataset including symptomatic and asymptomatic human carotid atherosclerosis plaques. Tissue sections of symptomatic and asymptomatic human carotid atherosclerotic plaques were analyzed by MALDI mass spectrometry imaging (MALDI MSI) of lipids, and adjacent sections analyzed by histology and immunofluorescence. These multimodal datasets were used to compare the lipid profiles of specific histopathological regions within the plaque. The lipid profiles of macrophage-rich regions and intimal vascular smooth muscle cells exhibited the largest changes associated with plaque outcome. Macrophage-rich regions from symptomatic lesions were found to be enriched in sphingomyelins, and intimal vascular smooth muscle cells of symptomatic plaques were enriched in cholesterol and cholesteryl esters. The proposed method enabled the MALDI MSI analysis of specific regions of the atherosclerotic lesion, confirming MALDI MSI as a promising tool for the investigation of histologically heterogeneous atherosclerotic plaques.

2 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
FGFrancesco Greco
Francesco Greco
Federica AnastasiFederica Anastasi
Federica Anastasi
LPLuca Fidia Pardini
Luca Fidia Pardini
MDMarialaura Dilillo
Marialaura Dilillo
Eleonora VanniniEleonora Vannini
Eleonora Vannini
LMLiam Andrew McDonnell
Liam Andrew McDonnell
Glioblastoma Multiforme (GBM) is a brain tumor with a poor prognosis and low survival rates. GBM is diagnosed at an advanced stage, so little information is available on the early stage of the disease and few improvements have been made for earlier diagnosis. Longitudinal murine models are a promising platform for biomarker discovery as they allow access to the early stages of the disease. Nevertheless, their use in proteomics has been limited owing to the low sample amount that can be collected at each longitudinal time point. Here we used optimized microproteomics workflows to investigate longitudinal changes in the protein profile of serum, serum small extracellular vesicles (sEVs), and cerebrospinal fluid (CSF) in a GBM murine model. Baseline, pre-symptomatic, and symptomatic tumor stages were determined using non-invasive motor tests. Forty-four proteins displayed significant differences in signal intensities during GBM progression. Dysregulated proteins are involved in cell motility, cell growth, and angiogenesis. Most of the dysregulated proteins already exhibited a difference from baseline at the pre-symptomatic stage of the disease, suggesting that early effects of GBM might be detectable before symptom onset.

8 August 2024 in Atherosclerosis
Verified
Journal Article
Closed access
FGFrancesco Greco
Francesco Greco
GBGiulia Bertagna
Giulia Bertagna
LQLaura Quercioli
Laura Quercioli
APAngela Pucci
Angela Pucci
SRSilvia Rocchiccioli
Silvia Rocchiccioli
LMLiam Andrew McDonnell
Liam Andrew McDonnell

4 March 2026 in Analytical Chemistry
Verified
Journal Article
Open access
FGFrancesco Greco
Francesco Greco
EMEllen McPhail
Ellen McPhail
DCDiana Canetti
Diana Canetti
AMAhmad Masri
Ahmad Masri
YCYu Fu Ferrari Chen
Yu Fu Ferrari Chen
GVGiuseppe Vergaro
Giuseppe Vergaro
Amyloidosis is a heterogeneous group of protein misfolding disorders characterized by the deposition of amyloid fibrils in tissues, which causes progressive organ dysfunction. Among the various forms, cardiac involvement by transthyretin (ATTR) and immunoglobulin light chain (AL) amyloidosis is particularly significant, as it is the main determinant of prognosis and treatment. In clinical practice, tissue biopsy remains crucial for diagnosing amyloidosis. Amyloid histological typing can be performed using antibody-based methods such as immunohistochemistry and immunoelectron microscopy. Mass spectrometry-based bottom-up proteomics has emerged as a powerful alternative, offering precise identification and quantification of amyloidogenic proteins. Despite being regarded as an effective technique for amyloid typing, the application of proteomics remains limited to specialized centers due to its technical complexity and lack of standardization in clinical workflows. This paper describes the current use of proteomics in patients with cardiac amyloidosis, based on the experience of referral centers in the USA and Europe, to provide guidance on improving the technique's reliability and to identify standard practices, challenges, and gaps in the clinical application of amyloidosis typing.

31 March 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
GFGianmarco Ferri
Gianmarco Ferri
FFFrancesco Finamore
Francesco Finamore
FGFrancesco Greco
Francesco Greco
AZAlessio Zanelli
Alessio Zanelli
FCFabrizia Carli
Fabrizia Carli
MDMaria Teresa Dell’ANno
Maria Teresa Dell’ANno
The shift from glycolysis to oxidative phosphorylation is a key step in neural differentiation. Yet, the timing of metabolic rewiring in the development from progenitors to neurons remains elusive, especially in human corticogenesis. To bridge this gap, here we adopted a unique cell platform based on neocortex-derived human neuroepithelial stem cells, modeling their physiological transition into functional neurons in a 4-mo longitudinal study and until the acquisition of electrophysiological competence. Using quantitative proteomics, combined with NAD(P)H fluorescence lifetime imaging and metabolomics, we investigated the entire differentiation process and describe how metabolic pathways drive cortical neuron maturation. The prevalent metabolic adaptations were then confirmed in a human neocortical specimen. This study provides a spatiotemporal map of neocortical metabolism during development and offers a framework to investigate human neurometabolic disorders.